Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.55 |
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667766 | 0.85 | KDM1A (0.44) | KDM1AMAOBMAOA | |
| SCHEMBL15901607 | 0.84 | KDM1A (0.44) | KDM1AMAOBMAOAKIF11SLC6A7 | |
| SCHEMBL15939515 | 0.81 | LMNA (0.56) | MAOBMAOA | |
| SCHEMBL15939514 | 0.81 | LMNA (0.56) | MAOBMAOA | |
| SCHEMBL1029212 | 0.77 | MAOA (0.46) | KDM1AMAOBMAOAKCNH2 | |
| SCHEMBL1029213 | 0.77 | MAOA (0.46) | KDM1AMAOBMAOAKCNH2 | |
| SCHEMBL15939493 | 0.76 | KDM1A (0.50) | KDM1AMAOBMAOA | |
| SCHEMBL15939494 | 0.76 | KDM1A (0.50) | KDM1AMAOBMAOA | |
| SCHEMBL14841626 | 0.75 | KDM1A (0.38) | KDM1AMAOA | |
| SCHEMBL1524298 | 0.75 | KDM1A (0.38) | KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859555-B2 | Lysine Specific Demethylase-1 inhibitors and their use | ORYZON GENOMICS S.A. (ES) | 2014-10-14 | — | — | US | disclosed |
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2012-11-08 | — | — | US | disclosed |
| WO-2011035941-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | JMJD6, KDM3A, KDM1A | KDM1A 3/4885MAOB 186/4885MAOA 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.